Role of thiopurine and anti-TNF therapy in lymphoma in inflammatory bowel disease

American Journal of Gastroenterology

Volumn 106, Issue 12, 2011, Pages 2146-2153

  Herrinton, Lisa J ^a   Liu, Liyan ^a   Weng, Xiaoping ^a   Lewis, James D ^b   Hutfless, Susan ^c   Allison, James E ^a,d  

^a DIVISION OF RESEARCH   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; INFLIXIMAB; MERCAPTOPURINE; TUMOR NECROSIS FACTOR ANTIBODY;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER INCIDENCE; CANCER REGISTRY; CANCER RISK; CHILD; COHORT ANALYSIS; CONTROLLED STUDY; CROHN DISEASE; DISEASE ASSOCIATION; DISEASE REGISTRY; DRUG EXPOSURE; DRUG SAFETY; DRUG UTILIZATION; FEMALE; FOLLICULAR LYMPHOMA; FOLLOW UP; HODGKIN DISEASE; HUMAN; INFANT; IRRITABLE COLON; LARGE CELL LYMPHOMA; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; ULCERATIVE COLITIS;

6-MERCAPTOPURINE; ADOLESCENT; ADULT; AGED; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; AZATHIOPRINE; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; INCIDENCE; INFANT; INFANT, NEWBORN; INFLAMMATORY BOWEL DISEASES; LYMPHOMA; MALE; MIDDLE AGED; RISK FACTORS; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 82955195113     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2011.283     Document Type: Article

References (12)

1. Brown SL, Greene MH, Gershon SK et al. Tumor necrosis factor antagonist therapy and lymphoma development: twenty-six cases reported to the Food and Drug Administration. Arthritis Rheum 2002; 46: 3151-8. (Pubitemid 35453523)
2. Liu L, Lewis JD, Griffi n PM et al. The positive predictive value of diagnoses for Crohn's disease, ulcerative colitis, and overall infl ammatory bowel disease in computerized data among members of Kaiser Permanente, Northern California, 1996-2002. Pharmacoepidemiol Drug Safety 2009; 18: 1086-93.
3. Surveillance, Epidemiology and End-Results. Standard Populations (Millions) for Age-Adjustment. http://seer.cancer.gov/stdpopulations/index.html Accessed 5 January 2011.
4. Garwood F. Fiducial limits for the Poisson distribution. Biometrica 1936; 28: 437-42.
5. Herrinton LJ, Liu L, Abramson O et al. The incidence of hepatosplenic γ T-cell lymphoma in a Large Northern California Health Plan, 2000-2006. Pharmacoepidemiol Drug Safety, 2011 Aug 8. doi: 10.1002/pds.2216 [E-pub ahead of print].
6. Bernstein CN, Blanchard JF, Kliewer E et al. Cancer risk in patients with infl ammatory bowel disease: a population-based study. Cancer 2001; 91: 854-62. (Pubitemid 32173312)
7. Lewis D, Bilker WB, Brensinger C et al. Infl ammatory bowel disease is not associated with an increased risk of lymphoma.[comment]. Gastroenterology 2001; 121: 1080-7. (Pubitemid 33022087)
8. Kandiel A, Fraser AG, Korelitz BI et al. Increased risk of lymphoma among infl ammatory bowel disease patients treated with azathioprine and 6-mercaptopurine. Gut 2005; 54: 1121-5. (Pubitemid 41025906)
9. Beaugerie L, Brousse N, Bouvier AM et al. for the CESAME Study Group. Lymphoproliferative disorders in patients receiving thiopurines for infl ammatory bowel disease: a prospective observational cohort study. Lancet 2009; 374: 1617-25.
10. Siegel CA, Marden SM, Persing SM et al. Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn's disease: a meta-analysis. Clin Gastroenterol Hepatol 2009; 7: 874-81.
11. Ekstr ö m Smedby K, Vajdic CM, Falster M et al. Autoimmune disorders and risk of non-Hodgkin lymphoma subtypes: a pooled analysis within the InterLymph Consortium. Blood 2008; 111: 4029-38.
12. Herrinton LJ. Epidemiology of the Revised European-American Lymphoma Classifi cation subtypes. Epidemiol Rev 1998; 20: 187-203. (Pubitemid 29045106)